AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition. The proposed acquisition will enrich AstraZeneca’s…
Bristol Myers Squibb and RayzeBio announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash…
AstraZeneca and Ionis Pharmaceuticals, Inc.’s Wainua (eplontersen) has been approved in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN. Wainua is the only approved medicine for the…
Chiesi Group, has been awarded the 59th Oscar di Bilancio for the Benefit Corporation category, sponsored by Federazione Relazioni Pubbliche Italiana, Borsa Italiana and Università Bocconi. The award ceremony entitled “Shared Value – The Future of Reporting is Written Today”…
Bristol Myers Squibb and Karuna Therapeutics announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for a total equity value of $14.0 billion, or $12.7 billion net of estimated…
Doctors from the Department of Plastic Surgery and Hand Surgery at the Universitätsspital Zürich created a new drain to relieve the patient’s agonizing lymph congestion. For the first time, a microsurgical operating system was used for such a procedure. By…
GSK and Hansoh Pharma, a Chinese biopharmaceutical company committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders, today announced that they have entered into an exclusive license agreement for HS-20093, a B7-H3 targeted antibody-drug…
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced today that FDA approved FILSUVEZ® (birch triterpenes) topical gel for the treatment of partial thickness…
Gilead Sciences today announced an agreement with Compugen, a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503…
Merck, known as MSD outside of the United States and Canada, announced the European Commission (EC) has approved two new indications for KEYTRUDA, Merck’s anti-PD-1 therapy, in gastrointestinal cancers: 👉 KEYTRUDA in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the…